Clinical Trials Logo

Metrorrhagia clinical trials

View clinical trials related to Metrorrhagia.

Filter by:

NCT ID: NCT00320580 Completed - Metrorrhagia Clinical Trials

An Open-Label Study to Compare the Bleeding Profile of Norelgestromin/Ethinyl Estradiol in an Extended Regimen to Norelgestromin/Ethinyl Estradiol Given in a Traditional Regimen

Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the bleeding profile of norelgestromin/ethinyl estradiol given in an extended continuous regimen to norelgestromin/ethinyl estradiol given in a traditional cyclic regimen

NCT ID: NCT00307801 Completed - Metrorrhagia Clinical Trials

Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding

Start date: February 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.

NCT ID: NCT00293059 Completed - Metrorrhagia Clinical Trials

Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding

Start date: December 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.

NCT ID: NCT00160381 Completed - Menorrhagia Clinical Trials

A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Uterine Fibroids

Start date: September 2002
Phase: Phase 3
Study type: Interventional

The objective of this study is to determine the safety and effectiveness of asoprisnil in symptomatic women with abnormal uterine bleeding associated with uterine fibroids.

NCT ID: NCT00156208 Completed - Uterine Fibroids Clinical Trials

Safety of Treatment of Uterine Fibroids With Asoprisnil

Start date: April 2004
Phase: Phase 3
Study type: Interventional

The objective of this study is to determine the long-term safety of asoprisnil in women with symptomatic uterine fibroids who completed the 6 month Study C02-037.

NCT ID: NCT00156195 Completed - Menorrhagia Clinical Trials

Study to Evaluate the Safety of Asoprisnil in the Treatment of Uterine Fibroids

Start date: September 2003
Phase: Phase 3
Study type: Interventional

The objective of this study is to determine the long-term safety of asoprisnil in women with abnormal uterine bleeding associated with uterine fibroids.

NCT ID: NCT00156156 Completed - Uterine Fibroids Clinical Trials

Study of Asoprisnil in the Treatment of Uterine Fibroids.

Start date: November 2004
Phase: Phase 3
Study type: Interventional

The objective of this study is to determine the long-term safety of asoprisnil in women with abnormal uterine bleeding associated with uterine fibroids.

NCT ID: NCT00152269 Completed - Menorrhagia Clinical Trials

Treatment of Uterine Fibroids With Asoprisnil(J867)

Start date: July 2002
Phase: Phase 3
Study type: Interventional

The objective of this study is to determine the safety and effectiveness of asoprisnil in symptomatic women with abnormal uterine bleeding associated with uterine fibroids.

NCT ID: NCT00152256 Completed - Uterine Fibroids Clinical Trials

A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids

Start date: September 2003
Phase: Phase 3
Study type: Interventional

The objective of this study is to determine the safety and efficacy effects of two doses of asoprisnil (10 mg and 25 mg) compared with placebo when administered daily for 6 months to premenopausal subjects with symptomatic uterine leiomyomata.

NCT ID: NCT00120913 Completed - Clinical trials for Breakthrough Bleeding

Continuous Oral Contraceptives (COCs): Are Bleeding Patterns Dependent on the Hormones Given?

Start date: n/a
Phase: N/A
Study type: Interventional

While there may be a decrease in the total number of bleeding days women experience with continuous-dosed COCs (no menstrual withdrawal week), these regimens frequently result in an increased number of “breakthrough” or non-scheduled bleeding days. Breakthrough bleeding is among the main reasons cited for discontinuation of combined COCs dosed traditionally (3 weeks of active pill, 1 week of placebo) or continuously, and may offset the perceived benefit of fewer withdrawal bleeding events for many women taking continuous-dosed COCs. The exact mechanisms responsible for breakthrough bleeding patterns during hormonal contraception are unknown and may be related to the pill formulation. This study is to determine whether progestin type or estrogen dose influences bleeding patterns, side effects, or satisfaction with combined oral contraceptives (COC) dosed continuously.